IDH mutations have been associated with better prognosis in high-grade gliomas (IDH mutant grade 4 astrocytomas are no longer considered “true” GBM in the 2021 WHO classification). This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).